<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006171</url>
  </required_header>
  <id_info>
    <org_study_id>CNP</org_study_id>
    <nct_id>NCT04006171</nct_id>
  </id_info>
  <brief_title>Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women</brief_title>
  <acronym>CNP</acronym>
  <official_title>C Type Natriuretic Peptide and Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Near East University, Turkey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Near East University, Turkey</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have shown that C natriuretic peptide is produced from granulosa cells,
      increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells
      through natriuretic peptide receptors. It is suggested that produced cGMP maintains the
      transport of oocytes via the gap junctions and leads to a continuous increase in cyclic
      adenosine monophosphate (cAMP) levels in the oocyte. An important role of increased internal
      cAMP levels in the oocyte is shown to suppress meiotic progression.

      Deoxyribonucleic acid studies in animals have shown that expression of the natriuretic
      peptide precursor increases during the periovulatory period and shows that this increase
      decreases rapidly after luteinizing hormone / human chorionic gonadotropin (hCG)
      stimulation.Human studies have shown that after ovulation induction, the CNP level in
      follicular fluid decreases following ovulatory dose of hCG.Polycystic ovary syndrome (PCOS)
      is the most common endocrine disease in the reproductive period, characterized by
      hyperandrogenism, oligo-anovulation, and polycystic ovarian morphology on ultrasonography,
      and in an animal study investigating the relationship between CNP and PCOS, serum CNP levels
      were increased in polycystic ovary syndrome.CNP serum level is thought to show differences
      between healthy women and women with polycystic ovary syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CNP and PCOS</measure>
    <time_frame>two months</time_frame>
    <description>Serum CNP levels of PCOS patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNP and Healthy women</measure>
    <time_frame>two months</time_frame>
    <description>Serum CNP levels of normal menstruating healthy women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare CNP</measure>
    <time_frame>Two months</time_frame>
    <description>Comparison of CNP levels in PCOS and healthy women</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>c Type Natriuretic Peptide</condition>
  <condition>Menstrual Irregularity</condition>
  <condition>Hyperandrogenism</condition>
  <arm_group>
    <arm_group_label>women with polycystic ovary syndrome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 patients with PCOS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy women of reproductive age</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 patients with regular normal menstrual cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>C type natriuretic peptide</intervention_name>
    <description>Serum level of CNP in PCOS and healthy women</description>
    <arm_group_label>Healthy women of reproductive age</arm_group_label>
    <arm_group_label>women with polycystic ovary syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS defined according to Rotterdam criteria

          -  Healthy normal menstruating women

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Cardiavascular disease

          -  Renal disease

          -  Any drug usage

          -  Smoking

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Özay</last_name>
    <role>Principal Investigator</role>
    <affiliation>Near East University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ali C Özay, MD</last_name>
    <phone>00903926751000</phone>
    <phone_ext>1341</phone_ext>
    <email>dr.alicenk@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Özlen Emekçi Özay, MD</last_name>
    <phone>00903926751000</phone>
    <phone_ext>1349</phone_ext>
    <email>ozlenemekci@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Near East University Faculty of Medicine</name>
      <address>
        <city>Nicosia</city>
        <zip>99138</zip>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cyprus</country>
  </location_countries>
  <results_reference>
    <citation>Zhang M, Su YQ, Sugiura K, Xia G, Eppig JJ. Granulosa cell ligand NPPC and its receptor NPR2 maintain meiotic arrest in mouse oocytes. Science. 2010 Oct 15;330(6002):366-9. doi: 10.1126/science.1193573.</citation>
    <PMID>20947764</PMID>
  </results_reference>
  <results_reference>
    <citation>Norris RP, Ratzan WJ, Freudzon M, Mehlmann LM, Krall J, Movsesian MA, Wang H, Ke H, Nikolaev VO, Jaffe LA. Cyclic GMP from the surrounding somatic cells regulates cyclic AMP and meiosis in the mouse oocyte. Development. 2009 Jun;136(11):1869-78. doi: 10.1242/dev.035238.</citation>
    <PMID>19429786</PMID>
  </results_reference>
  <results_reference>
    <citation>Vaccari S, Weeks JL 2nd, Hsieh M, Menniti FS, Conti M. Cyclic GMP signaling is involved in the luteinizing hormone-dependent meiotic maturation of mouse oocytes. Biol Reprod. 2009 Sep;81(3):595-604. doi: 10.1095/biolreprod.109.077768. Epub 2009 May 27.</citation>
    <PMID>19474061</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsafriri A, Chun SY, Zhang R, Hsueh AJ, Conti M. Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors. Dev Biol. 1996 Sep 15;178(2):393-402.</citation>
    <PMID>8812137</PMID>
  </results_reference>
  <results_reference>
    <citation>Thomas RE, Armstrong DT, Gilchrist RB. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Dev Biol. 2002 Apr 15;244(2):215-25.</citation>
    <PMID>11944932</PMID>
  </results_reference>
  <results_reference>
    <citation>Nogueira D, Albano C, Adriaenssens T, Cortvrindt R, Bourgain C, Devroey P, Smitz J. Human oocytes reversibly arrested in prophase I by phosphodiesterase type 3 inhibitor in vitro. Biol Reprod. 2003 Sep;69(3):1042-52. Epub 2003 May 28.</citation>
    <PMID>12773402</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee KB, Zhang M, Sugiura K, Wigglesworth K, Uliasz T, Jaffe LA, Eppig JJ. Hormonal coordination of natriuretic peptide type C and natriuretic peptide receptor 3 expression in mouse granulosa cells. Biol Reprod. 2013 Feb 21;88(2):42. doi: 10.1095/biolreprod.112.104810. Print 2013 Feb.</citation>
    <PMID>23255339</PMID>
  </results_reference>
  <results_reference>
    <citation>Hiradate Y, Hoshino Y, Tanemura K, Sato E. C-type natriuretic peptide inhibits porcine oocyte meiotic resumption. Zygote. 2014 Aug;22(3):372-7. doi: 10.1017/S0967199412000615. Epub 2013 Jan 18.</citation>
    <PMID>23331536</PMID>
  </results_reference>
  <results_reference>
    <citation>Kawamura K, Cheng Y, Kawamura N, Takae S, Okada A, Kawagoe Y, Mulders S, Terada Y, Hsueh AJ. Pre-ovulatory LH/hCG surge decreases C-type natriuretic peptide secretion by ovarian granulosa cells to promote meiotic resumption of pre-ovulatory oocytes. Hum Reprod. 2011 Nov;26(11):3094-101. doi: 10.1093/humrep/der282. Epub 2011 Aug 23.</citation>
    <PMID>21865234</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang X, Wang H, Liu W, Zhang Z, Zhang Y, Zhang W, Chen Z, Xia G, Wang C. High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice. Clin Sci (Lond). 2018 Apr 6;132(7):759-776. doi: 10.1042/CS20171394. Print 2018 Apr 16.</citation>
    <PMID>29535265</PMID>
  </results_reference>
  <results_reference>
    <citation>Reis AM, Honorato-Sampaio K. C-type natriuretic peptide: a link between hyperandrogenism and anovulation in a mouse model of polycystic ovary syndrome. Clin Sci (Lond). 2018 May 8;132(9):905-908. doi: 10.1042/CS20171491. Print 2018 May 16.</citation>
    <PMID>29739821</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 5, 2019</last_update_submitted>
  <last_update_submitted_qc>July 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Near East University, Turkey</investigator_affiliation>
    <investigator_full_name>Ali Cenk</investigator_full_name>
    <investigator_title>Medical Doctor, assistant professor</investigator_title>
  </responsible_party>
  <keyword>c type natriuretic peptide</keyword>
  <keyword>polycystic ovary syndrome</keyword>
  <keyword>menstrual cycle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Menstruation Disturbances</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, C-Type</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

